ABSTRACT
A substantial proportion of acute SARS-CoV2 infection cases exhibit gastrointestinal symptoms, yet the genetic determinants of these extrapulmonary manifestations are poorly understood. Using survey data from 239,866 individuals who tested positively for SARS-CoV2, we conducted a multi-ancestry GWAS of 80,289 cases of diarrhea occurring during acute COVID-19 infection (33.5%). Six loci (CYP7A1, LZFTl1- - CCR9, TEME182, NALCN, LFNG, GCKR) met genome-wide significance in a trans-ancestral analysis. The top significant GWAS hit mapped to the CYP7A1 locus, which plays an etiologic role in bile acid metabolism and is in high LD (r2= 0.93) with the SDCBP gene, which was previously implicated in antigen processing and presentation in the COVID-19 context. Another association was observed with variants in the LZTFL1–CCR9 region, which is a known locus for COVID-19 susceptibility and severity. PheWAS showed a shared association across three of the six SNPs with irritable bowel syndrome (IBS) and its subtypes. Mendelian randomization showed that genetic liability to IBS-diarrhea increased (OR=1.40,95%,CI[1.33-1.47]), and liability to IBS-constipation decreased (OR=0.86, 95%CI[0.79-0.94]) the relative odds of experiencing COVID-19+ diarrhea. Our genetic findings provide etiological insights into the extrapulmonary manifestations of acute SARS-CoV2 infection.
Competing Interest Statement
C.H.W, P.N, S,A, and M.V.H are current employees of 23andMe and hold stock or stock options in 23andMe. J.S is a current employee of Bristol Myers Squibb. N.S.C works as a postdoctoral fellow on the 23andMe Genetic Epidemiology Team.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The surveys were distributed to individuals who provided informed consent and volunteered to participate in the research online, under a protocol approved by the external AAHRPP-accredited IRB, Ethical & Independent (E&I) Review Services. As of 2022, E&I Review Services is part of Salus IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* joint senior authors
